Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.69 |
| ▸ | WIZ | O95785 | 1/20 | 0.63 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552859 | 1.00 | CRBN (0.69) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL19503629 | 0.91 | CRBN (0.72) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL21464461 | 0.89 | WIZ (0.55) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25996067 | 0.88 | CRBN (0.69) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL23267660 | 0.88 | CRBN (0.62) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL30851278 | 0.87 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL19503638 | 0.87 | CRBN (0.65) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL22566723 | 0.87 | IKZF2 (0.65) | CRBNWIZIKZF2 | |
| SCHEMBL22828005 | 0.87 | CRBN (0.65) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25988439 | 0.86 | CRBN (0.70) | CRBNWIZIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | CRBN 1/4885WIZ 1242/4885IKZF2 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.